Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

1306 - Poor-prognosis Locally Advanced Rectal Cancer is Defined by a Molecularly Distinct Subtype


24 Nov 2018


Poster display - Cocktail


Pathology/Molecular Biology

Tumour Site

Colon and Rectal Cancer


Jing Zhang


Annals of Oncology (2018) 29 (suppl_9): ix28-ix45. 10.1093/annonc/mdy431


J. Zhang, L. Shen, Y. Wang, Y. Deng, L. Yang, J. Wan, Z. Zhang

Author affiliations

  • Radiation Oncology, Shanghai Cancer Center Fudan University, 200032 - Shanghai/CN


Abstract 1306


TNM stage is still the only prognostic tool used in clinical practice to treat patients but it fails to accurately predict outcomes. Categorization of locally advanced rectal cancers into distinct subtypes using a combination of qPCR-based biomarkers could provide insight into variability in outcomes.


We used a PCR-based assay to detect 30 genes (LARCassigner-30) in 197 locally advanced rectal cancer samples, collected prospectively from patients treated with neoadjuvant chemoradiation and surgery from January 2007 to December 2012 in Fudan University Shanghai Cancer Center. 197 patients were randomly divided into training queuing of 98 cases and validation of the cohort of 99 cases. Median follow-up time is 58 months. Association with 5-year overall survival, disease-free survival, recurrent rate and metastatic rate was evaluated using Cox proportional hazards models.


Baseline clinical characteristics and postoperative pathological features were similar between the training cohort and the validation cohort. The overall survival rate of LARCassigner-30 type 1 patients was lower than that of type 2 patients in the training and validation cohorts (p < 0.01), tumor-free survival rate decreased (p < 0.01); local recurrence rate increased (p < 0.01), distant metastasis rate increased (p < 0.01), the difference was statistically significant. In the training cohort, LARCassigner-30 type 1 patients with locally advanced rectal cancer were found to have poorer response to neoadjuvant chemoradiation than type 2 patients (p = 0.023), but they were not verified in the validation cohort.


We developed qPCR-based classifiers LARCassigner-30 that performs well at predicting the outcomes in locally advanced rectal cancer.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Institutional Review Board of Fudan University Shanghai Cancer Center.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.